Advertisement

Sex and Gender Differences in Neurology

  • Christian H. Nolte
  • Peter U. Heuschmann
  • Matthias Endres
Chapter

Abstract

Neurology deals with disorders of the nervous system that may involve its central, peripheral, and/or autonomic part and its effector tissue (particularly muscle). Sex and gender affects the incidence, prevalence, and dynamics of central nervous system (CNS) diseases. This chapter deals with examples of gender differences in neurological diseases and describes a broad variety of underlying pathologies. The examples given include nervous diseases of inflammatory (multiple sclerosis), vascular (stroke), and degenerative (Alzheimer’s and Parkinson’s) origin, as well as a functional state of increased vulnerability to seizures (Epilepsy) (Fig. 11.1).

Keywords

Multiple Sclerosis Multiple Sclerosis Patient Deep Brain Stimulation Optic Neuritis Glatiramer Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Rooney WD, Coyle PK. Recent advances in the neuroimaging of multiple sclerosis. Curr Neurol Neurosci Rep. 2005; 5:217-224.PubMedGoogle Scholar
  2. 2.
    Galanopoulou AS. GABA receptors as broadcasters of sexually differentiating signals in the brain. Epilepsia. 2005;46: 107-112.PubMedGoogle Scholar
  3. 3.
    Watzka M, Bidlingmaier F, Schramm J, Klingmuller D, Stoffel-Wagner B. Sex- and age-specific differences in human brain CYP11A1 mRNA expression. J Neuroendocrinol. 1999;11:901-905.PubMedGoogle Scholar
  4. 4.
    Kurtz J, Wiesner A, Götz P, Sauer KP. Gender differences and individual variation in the immune system of the scorpionfly Panorpa vulgaris (Insecta: Mecoptera). Dev Comp Immunol. 2000;24:1-12.PubMedGoogle Scholar
  5. 5.
    Da Silva JA. Sex hormones and glucocorticoids: interactions with the immune system. Ann N Y Acad Sci. 1999;876:102-118.PubMedGoogle Scholar
  6. 6.
    Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians. Br Med Bull. 2010;95:79-104.PubMedGoogle Scholar
  7. 7.
    Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stüve O. The increasing incidence and prevalence of female multiple sclerosis – a critical analysis of potential environmental factors. Autoimmun Rev. 2011;10(8):495-502. Epub 2011 Feb 24.PubMedGoogle Scholar
  8. 8.
    Alonso A, Jick SS, Olek MJ, Hernan MA. Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol. 2007;254:1736-1741.PubMedGoogle Scholar
  9. 9.
    Alonso A, Hernán MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008; 71:129-135.PubMedGoogle Scholar
  10. 10.
    Ness JM, Chabas D, Sadovnick AD, et al. Clinical features of children and adolescents with multiple sclerosis. Neurology. 2007;68:S37-S45.PubMedGoogle Scholar
  11. 11.
    Steinman L. Autoimmune disease. Sci Am. 1993;269:106-114.PubMedGoogle Scholar
  12. 12.
    Gilmore W, Weiner LP, Correale J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol. 1997;158:446-451.PubMedGoogle Scholar
  13. 13.
    Drew PD, Chavis JA. Female sex steroids: effects upon microglial cell activation. J Neuroimmunol. 2000;111:77-85.PubMedGoogle Scholar
  14. 14.
    Schwendimann RN, Alekseeva N. Gender issues in multiple sclerosis. Int Rev Neurobiol. 2007;79:377-392.PubMedGoogle Scholar
  15. 15.
    Kim S, Voskuhl RR. Decreased IL-12 production underlies the decreased ability of male lymph node cells to induce experimental autoimmune encephalomyelitis. J Immunol. 1999;162:5561-5568.PubMedGoogle Scholar
  16. 16.
    Palaszynski KM, Loo KK, Ashouri JF, Liu HB, Voskuhl RR. Androgens are protective in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol. 2004;146:144-152.PubMedGoogle Scholar
  17. 17.
    Kuhlmann T, Goldschmidt T, Antel J, et al. Gender differences in the histopathology of MS? J Neurol Sci. 2009;15(286):86-91.Google Scholar
  18. 18.
    van Walderveen MA et al. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol. 2001;58:76-81.PubMedGoogle Scholar
  19. 19.
    Antulov R et al. Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Mult Scler. 2009;15:345-354.PubMedGoogle Scholar
  20. 20.
    Fazekas F, Enzinger C, Wallner-Blazek M, Ropele S, Pluta-Fuerst A, Fuchs S. Gender differences in MRI studies on multiple sclerosis. J Neurol Sci. 2009;286:28-30.PubMedGoogle Scholar
  21. 21.
    Shibasaki H, Kuroiwa Y. Sex difference of multiple sclerosis in Japan. Neurology. 1976;26:821-824.PubMedGoogle Scholar
  22. 22.
    Vein AM, Voznesenskaia TG, Khromova LG. The course of disseminated sclerosis in men and women. Zh Nevrol Psikhiatr Im S S Korsakova. 1995;95:43-44.PubMedGoogle Scholar
  23. 23.
    Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry. 2005;76:272-275.PubMedGoogle Scholar
  24. 24.
    Bever CT Jr, McFarlin DE, Levy HB. A comparison of interferon responses to poly ICLC in males and females. J Interferon Res. 1985;5:423-428.PubMedGoogle Scholar
  25. 25.
    Bever CT Jr, McFarland HF, McFarlin DE, Levy HB. The kinetics of interferon induction by poly ICLC in humans. J Interferon Res. 1988;8:419-425.PubMedGoogle Scholar
  26. 26.
    Gulick EE. Social support among persons with multiple sclerosis. Res Nurs Health. 1994;17:195-206.PubMedGoogle Scholar
  27. 27.
    Good DM, Bower DA, Einsporn RL. Social support: gender differences in multiple sclerosis spousal caregivers. J Neurosci Nurs. 1995;27:305-311.PubMedGoogle Scholar
  28. 28.
    Steck B, Amsler F, Kappos L, Burgin D. Gender-specific differences in the process of coping in families with a parent affected by a chronic somatic disease (e.g. multiple sclerosis). Psychopathology. 2001;34:236-244.PubMedGoogle Scholar
  29. 29.
    Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339:285-291.PubMedGoogle Scholar
  30. 30.
    Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 1995;118:253-261.PubMedGoogle Scholar
  31. 31.
    Coyle PK, Johnson K, Stark Y, Pardo L. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). J Neurol Neurosurg Psychiatry. 2003;74:443.Google Scholar
  32. 32.
    Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain. 2004;127:1463-1478.PubMedGoogle Scholar
  33. 33.
    Beatty WW, Aupperle RL. Sex differences in cognitive impairment in multiple sclerosis. Clin Neuropsychol. 2002;16:472-480.PubMedGoogle Scholar
  34. 34.
    Fraser C, Polito S. A comparative study of self-efficacy in men and women with multiple sclerosis. J Neurosci Nurs. 2007;39:102-106.PubMedGoogle Scholar
  35. 35.
    Di Carlo A, Lamassa M, Baldereschi M, et al. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke. 2003;34:1114-1119.PubMedGoogle Scholar
  36. 36.
    Carandang R, Seshadri S, Beiser A, et al. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA. 2006;296:2939-2946.PubMedGoogle Scholar
  37. 37.
    Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25:135-143.PubMedGoogle Scholar
  38. 38.
    Niewada M, Kobayashi A, Sandercock PA, Kamiński B, Członkowska A, International Stroke Trial Collaborative Group. Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischaemic stroke in the international stroke trial. Neuroepidemiology. 2005;24:123-128.PubMedGoogle Scholar
  39. 39.
    Benatru I, Rouaud O, Durier J, et al. Stable stroke incidence rates but improved case-fatality in Dijon, France, from 1985 to 2004. Stroke. 2006;37:1674-1679.PubMedGoogle Scholar
  40. 40.
    Sheikh K, Bullock CM. Effect of measurement on sex difference in stroke mortality. Stroke. 2007;38:1085-1087.PubMedGoogle Scholar
  41. 41.
    Thorvaldsen P, Asplund K, Kuulasmaa K, Rajakangas AM, Schroll M. Stroke incidence, case fatality, and mortality in the WHO MONICA project. World Health Organization Monitoring Trends and Determinants in Cardiovascular Disease. Stroke. 1995;26:361-367.PubMedGoogle Scholar
  42. 42.
    Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72-78.PubMedGoogle Scholar
  43. 43.
    Lai SM, Duncan PW, Dew P, Keighley J. Sex differences in stroke recovery. Prev Chronic Dis. 2005;2:A13.PubMedGoogle Scholar
  44. 44.
    Barrett KM et al. Sex differences in stroke severity, symptoms, and deficits after first-ever ischemic stroke. J Stroke Cerebrovasc Dis. 2007;16:34-39.PubMedGoogle Scholar
  45. 45.
    Reid JM et al. Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital. Stroke. 2008;39:1090-1095.PubMedGoogle Scholar
  46. 46.
    Brown DL, Lisabeth LD, Garcia NM, Smith MA, Morgenstern LB. Emergency department evaluation of ischemic stroke and TIA: the BASIC Project. Neurology. 2004;63:2250-2254.PubMedGoogle Scholar
  47. 47.
    Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology. 2001;57:305-314.PubMedGoogle Scholar
  48. 48.
    Foerch C, Misselwitz B, Humpich M, et al. Sex disparity in the access of elderly patients to acute stroke care. Stroke. 2007;38:2123-2126.PubMedGoogle Scholar
  49. 49.
    Glader EL et al. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke. 2003;34:1970-1975.PubMedGoogle Scholar
  50. 50.
    Roquer J, Campello AR, Gomis M. Sex differences in first-ever acute stroke. Stroke. 2003;34:1581-1585.PubMedGoogle Scholar
  51. 51.
    del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003;23:879-894.PubMedGoogle Scholar
  52. 52.
    Gray LJ et al. Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). Stroke. 2007;38:2960-2964.PubMedGoogle Scholar
  53. 53.
    Everson SA, Roberts RE, Goldberg DE, Kaplan GA. Depressive symptoms and increased risk of stroke mortality over a 29-year period. Arch Intern Med. 1998;158:1133-1138.PubMedGoogle Scholar
  54. 54.
    Herrmann N, Black SE, Lawrence J, Szekely C, Szalai JP. The Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. Stroke. 1998;29:618-624.PubMedGoogle Scholar
  55. 55.
    Eriksson M, Asplund K, Glader EL, et al. Self-reported depression and use of antidepressants after stroke: a national survey. Stroke. 2004;35:936-941.PubMedGoogle Scholar
  56. 56.
    Kelly-Hayes M, Beiser A, Kase C, Scaramucci A, D’Agostino RB, Wolf PA. The influence of gender and age on disability following ischemic stroke: the Framingham study. J Stroke Cerebrovasc Dis. 2003;12:119-126.PubMedGoogle Scholar
  57. 57.
    Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke. 2000;31:1833-1837.PubMedGoogle Scholar
  58. 58.
    Theodore WH, Spencer SS, Wiebe S, et al. Epilepsy in North America: a report prepared under the auspices of the global campaign against epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization. Epilepsia. 2006;47:1700-1722.PubMedGoogle Scholar
  59. 59.
    Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res. 2007;76:60-65.PubMedGoogle Scholar
  60. 60.
    McHugh JC, Delanty N. Epidemiology and classification of epilepsy: gender comparisons. Int Rev Neurobiol. 2008;83:11-26.PubMedGoogle Scholar
  61. 61.
    van Merode T, de Krom MC, Knottnerus JA. Gender-related differences in non-epileptic attacks: a study of patients’ cases in the literature. Seizure. 1997;6(4):311-316.PubMedGoogle Scholar
  62. 62.
    Pennell PB, Thompson P. Gender-specific psychosocial impact of living with epilepsy. Epilepsy Behav. 2009;15:S20-S25.PubMedGoogle Scholar
  63. 63.
    Herzog AG. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure. 2008; 17:101-110.PubMedGoogle Scholar
  64. 64.
    Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol. 2004;56:431-434.PubMedGoogle Scholar
  65. 65.
    Morrell MJ. Epilepsy in women: the science of why it is special. Neurology. 1999;53:S42-S48.PubMedGoogle Scholar
  66. 66.
    Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47:1447-1451.PubMedGoogle Scholar
  67. 67.
    Tan M, Tan U. Sex difference in susceptibility to epileptic seizures in rats: importance of estrous cycle. Int J Neurosci. 2001;108:175-191.PubMedGoogle Scholar
  68. 68.
    Janszky J, Schulz R, Janszky I, Ebner A. Medial temporal lobe epilepsy: gender differences. J Neurol Neurosurg Psychiatry. 2004;75:773-775.PubMedGoogle Scholar
  69. 69.
    Falip M et al. Classic antiepileptic and new generation antiepileptic drugs: gender differences in effectiveness and adverse drug reactions. Neurologia. 2005;20:71-76.PubMedGoogle Scholar
  70. 70.
    Harden CL. Issues for mature women with epilepsy. Int Rev Neurobiol. 2008;83:385-395.PubMedGoogle Scholar
  71. 71.
    Lackner TE, Cloyd JC, Thomas LW, Leppik IE. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia. 1998;39:1083-1087.PubMedGoogle Scholar
  72. 72.
    Pita Calandre E. Adverse reactions and interactions of antiepileptic drugs in epileptic women. Rev Neurol. 2002;34:466-470.PubMedGoogle Scholar
  73. 73.
    Mazziotti G, Canalis E, Giustina A. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010;123:877-884.PubMedGoogle Scholar
  74. 74.
    Hitiris N, Suratman S, Kelly K, Stephen LJ, Sills GJ, Brodie MJ. Sudden unexpected death in epilepsy: a search for risk factors. Epilepsy Behav. 2007;10:138-141.PubMedGoogle Scholar
  75. 75.
    Kumlien E. Treatment outcome in patients with mesial temporal sclerosis. Seizure. 2002;11:413-417.PubMedGoogle Scholar
  76. 76.
    Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S4-S9.PubMedGoogle Scholar
  77. 77.
    Berr C, Wancata J, Ritchie K. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol. 2005;15:463-471.PubMedGoogle Scholar
  78. 78.
    Harvey RJ, Skelton-Robinson M, Rossor MN. The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003;74:1206-1209.PubMedGoogle Scholar
  79. 79.
    Fratiglioni L, Launer LJ, Andersen K, et al. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S10-S15.PubMedGoogle Scholar
  80. 80.
    Alvarez-de-la-Rosa M et al. Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimer’s disease. Ann N Y Acad Sci. 2005;1052:210-224.PubMedGoogle Scholar
  81. 81.
    Lloret A, Badía MC, Mora NJ, et al. Gender and age-dependent differences in the mitochondrial apoptogenic pathway in Alzheimer’s disease. Free Radic Biol Med. 2008;44:2019-2025.PubMedGoogle Scholar
  82. 82.
    Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62:685-691.PubMedGoogle Scholar
  83. 83.
    Barnes LL, Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Gender, cognitive decline, and risk of AD in older persons. Neurology. 2003;60:1777-1781.PubMedGoogle Scholar
  84. 84.
    Ott BR, Tate CA, Gordon NM, Heindel WC. Gender differences in the behavioral manifestations of Alzheimer’s disease. J Am Geriatr Soc. 1996;44:583-587.PubMedGoogle Scholar
  85. 85.
    Schmidt R, Kienbacher E, Benke T, et al. Sex differences in Alzheimer’s disease. Neuropsychiatr. 2008;22:1-15.PubMedGoogle Scholar
  86. 86.
    Cohen D, Eisdorfer C, Gorelick P, et al. Sex differences in the psychiatric manifestations of Alzheimer’s disease. J Am Geriatr Soc. 1993;41:229-232.PubMedGoogle Scholar
  87. 87.
    Buchanan RJ, Wang S, Ju H, Graber D. Analyses of gender differences in profiles of nursing home residents with Alzheimer’s disease. Gend Med. 2004;1:48-59.PubMedGoogle Scholar
  88. 88.
    Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, in healthy subjects and patients. Curr Clin Pharmacol. 2010;5:115-124.PubMedGoogle Scholar
  89. 89.
    Hernandez S, McClendon MJ, Zhou XH, Sachs M, Lerner AJ. Pharmacological treatment of Alzheimer’s disease: effect of race and demographic variables. J Alzheimers Dis. 2010;19:665-672.PubMedGoogle Scholar
  90. 90.
    Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. Italian longitudinal study on aging. Neurology. 2000;55:1358-1363.PubMedGoogle Scholar
  91. 91.
    Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology. 1999;52:1214-1220.PubMedGoogle Scholar
  92. 92.
    Alves G, Müller B, Herlofson K, et al. Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry. 2009;80:851-857.PubMedGoogle Scholar
  93. 93.
    Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry. 2004;75:637-639.PubMedGoogle Scholar
  94. 94.
    Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:905-906.PubMedGoogle Scholar
  95. 95.
    Mayeux R et al. The frequency of idiopathic Parkinson’s disease by age, ethnic group, and sex in northern Manhattan, 1988–1993. Am J Epidemiol. 1995;142:820-827.PubMedGoogle Scholar
  96. 96.
    Haaxma CA et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:819-824.PubMedGoogle Scholar
  97. 97.
    Diem-Zangerl A, Seppi K, Wenning GK, et al. Mortality in Parkinson’s disease: a 20-year follow-up study. Mov Disord. 2009;24:819-825.PubMedGoogle Scholar
  98. 98.
    Ragonese P, D’Amelio M, Salemi G, et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology. 2004;62:2010-2014.PubMedGoogle Scholar
  99. 99.
    Popat RA, Van Den Eeden SK, Tanner CM, et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology. 2005;65:383-390.PubMedGoogle Scholar
  100. 100.
    Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol. 2004;61:886-888.PubMedGoogle Scholar
  101. 101.
    Fernandez HH, Lapane KL, Ott BR, Friedman JH. Gender differences in the frequency and treatment of behavior problems in Parkinson’s disease. SAGE Study Group. Systematic Assessment and Geriatric drug use via Epidemiology. Mov Disord. 2000;15:490-496.PubMedGoogle Scholar
  102. 102.
    Cantuti-Castelvetri I et al. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol Dis. 2007;26:606-614.PubMedGoogle Scholar
  103. 103.
    Zeller EA et al. Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase. J Neural Transm. 1976;39:63-77.PubMedGoogle Scholar
  104. 104.
    Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson’s disease. Clin Neuropharmacol. 1998;21:118-121.PubMedGoogle Scholar
  105. 105.
    Nazem S, Siderowf AD, Duda JE, et al. Montreal cognitive assessment performance in patients with Parkinson’s disease with “normal” global cognition according to mini-mental state examination score. J Am Geriatr Soc. 2009;57:304-308.PubMedGoogle Scholar
  106. 106.
    Shulman LM. Gender differences in Parkinson’s disease. Gend Med. 2007;4:8-18.PubMedGoogle Scholar
  107. 107.
    Scott B, Borgman A, Engler H, Johnels B, Aquilonius SM. Gender differences in Parkinson’s disease symptom profile. Acta Neurol Scand. 2000;102:37-43.PubMedGoogle Scholar
  108. 108.
    Biglan KM, Holloway RG Jr, McDermott MP, Richard IH, Parkinson Study Group CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology. 2007;69:187-195.PubMedGoogle Scholar
  109. 109.
    Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005;62:601-605.PubMedGoogle Scholar
  110. 110.
    Accolla E et al. Gender differences in patients with Parkinson’s disease treated with subthalamic deep brain stimulation. Mov Disord. 2007;22:1150-1156.PubMedGoogle Scholar
  111. 111.
    Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with Parkinson’s disease. Neurology. 2000;55:1572-1575.PubMedGoogle Scholar
  112. 112.
    Arabia G et al. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson’s disease. Neurol Sci. 2002;23: S53-S54.PubMedGoogle Scholar
  113. 113.
    Zappia M et al. Body weight influences pharmacokinetics of levodopa in Parkinson’s disease. Clin Neuropharmacol. 2002;25:79-82.PubMedGoogle Scholar
  114. 114.
    Hariz GM, Hariz I. Gender distribution in surgery for Parkinson’s disease. Parkinsonism Relat Disord. 2000;6:155-157.PubMedGoogle Scholar
  115. 115.
    Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR, Study of Osteoporotic Fractures (SOF) Research Group. The association of Parkinson’s disease with bone mineral density and fracture in older women. Osteoporos Int. 2008;19:1093-1097.PubMedGoogle Scholar
  116. 116.
    Hariz GM, Lindberg M, Hariz MI, Bergenheim AT. Gender differences in disability and health-related quality of life in patients with Parkinson’s disease treated with stereotactic surgery. Acta Neurol Scand. 2003;108:28-37.PubMedGoogle Scholar
  117. 117.
    Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69:308-312.PubMedGoogle Scholar
  118. 118.
    Freye C. Hormonal Influences on Seizures: Basic Neurobiology. Int Review of Neurobiology (2008) 83:27-77. J Neurol Neurosurg Psychiatry. 2000;69:308-312.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  • Christian H. Nolte
    • 1
  • Peter U. Heuschmann
    • 2
  • Matthias Endres
    • 3
  1. 1.Department of NeurologyCharité University MedicineBerlinGermany
  2. 2.Center for Stroke Research BerlinCharité University MedicineBerlinGermany
  3. 3.Department of Neurology and Center for Stroke Research BerlinCharité University MedicineBerlinGermany

Personalised recommendations